Recursion director granted 88,424 stock units

Borgeson Blake reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Borgeson Blake reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS, INC. director Blake Borgeson received a grant of 88,424 shares of Class A common stock in the form of restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to his continued service. Following this award, he directly holds 6,258,287 shares.

Insider Trade Summary

Grant/Award: 88,424 shares

Grant/Award 1 txn

Insider Borgeson Blake

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	88,424	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 6,258,287 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Key Figures

RSU grant size: 88,424 shares Grant price: $0.00 per share Holdings after grant: 6,258,287 shares +1 more

4 metrics

RSU grant size 88,424 shares Restricted stock units awarded to director on June 17, 2026

Grant price $0.00 per share Compensation grant, not open-market purchase

Holdings after grant 6,258,287 shares Total Class A common stock directly held after transaction

Vesting date June 17, 2027 RSUs vest by this date or day before 2027 annual meeting

Key Terms

restricted stock units, Outside Director Compensation Policy, Annual Meeting of Stockholders, Class A Common Stock, +1 more

5 terms

restricted stock units financial

"Represents a grant of restricted stock units automatically granted pursuant"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Outside Director Compensation Policy financial

"automatically granted pursuant to the Issuer's Outside Director Compensation Policy"

Annual Meeting of Stockholders financial

"the day prior to the Issuer's 2027 Annual Meeting of Stockholders"

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Recursion Pharmaceuticals (RXRX) director Blake Borgeson report in this Form 4?

Blake Borgeson reported receiving 88,424 restricted stock units of Class A common stock. The grant was made under Recursion’s Outside Director Compensation Policy and increased his direct holdings to 6,258,287 shares after the transaction.

How many Recursion (RXRX) shares did Blake Borgeson acquire in this award?

He acquired 88,424 shares of Class A common stock in the form of restricted stock units. The award carried a stated price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase.

When do Blake Borgeson’s new Recursion (RXRX) restricted stock units vest?

The restricted stock units vest on the earlier of June 17, 2027 or the day prior to Recursion’s 2027 Annual Meeting of Stockholders, provided Blake Borgeson continues to serve the company as an outside director through that date.

What are Blake Borgeson’s total Recursion (RXRX) holdings after this Form 4 transaction?

After the grant, Blake Borgeson directly holds 6,258,287 shares of Recursion’s Class A common stock. This total includes the newly awarded 88,424 restricted stock units reported in the Form 4 insider transaction filing.

Was Blake Borgeson’s Recursion (RXRX) grant an open-market purchase or compensation award?

The transaction was a compensation award, not an open-market purchase. It is coded as a grant or award acquisition, with restricted stock units automatically granted under Recursion’s Outside Director Compensation Policy at a stated price of $0.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/17/2026		A(1)		88,424	A	$0	6,258,287	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/Jonathan Golightly, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)